Table 2.

Molecular characteristics of the DIPG patients’ cohort treated with or without target therapies.

	Target therapy	No target therapy
Number (%)	9 (36%)	16 (64%)
Histological and IHC findings
Hypercellularity
Yes, n (%)	5 (55.5)	10 (62.5)
No, n (%)	4 (44.5)	6 (37.5)
Data missing, n (%)	0 (0)	(0)
Mitoses
Low, n (%)	4 (44.5)	9 (56)
High, n (%)	3 (33.5)	4 (25)
Data missing, n (%)	2 (22)	(19)
Atypia
Mild, n (%)	4 (44.5)	8 (50)
Moderate, n (%)	4 (44.5)	6 (37.5)
Severe, n (%)	1 (11)	2 (12.5)
Data missing, n (%)	0 (0)	(0)
Ki67 expression
⩽5%, n (%)	3 (33.3)	1 (6.25)
5–15%, n (%)	3 (33.3)	8 (50)
>15%, n (%)	2 (22.3)	5 (31.25)
Data missing, n (%)	1 (11.1)	(12.5)
P53 expression
>50%, n (%)	2 (22)	8 (50)
<50%, n (%)	5 (56)	5 (31.25)
Data missing, n (%)	2 (22)	(18.75)
ATRX
Maintained, n (%)	5 (55.6)	9 (56.25)
Lost, n (%)	2 (22.2)	3 (18.75)
Data missing, n (%)	2 (22.2)	(25)
H3K27 me3
Maintained, n (%)	1 (11.1)	0 (0)
Lost, n (%)	8 (88.9)	11 (68.75)
Data missing, n (%)	0 (0)	5 (31.25)
H3K27M IHC
Positivity, n (%)	8 (89)	16 (100)
Negativity, n (%)	1 (11)	0 (0)
Data missing, n (%)	0 (0)	(0)
BRAF IHC
Expressed, n (%)	1 (11)	0 (0)
Not expressed, n (%)	4 (44,5)	10 (62.5)
Data missing, n (%)	4 (44,5)	(37.5)
mTOR/pm-TOR IHC
Expressed, n (%)	7 (78)	3 (19)
Not expressed, n (%)	0 (0)	4 (25)
Data missing, n (%)	2 (22)	9 (56)
Molecular findings
Histone mutation detection	8 (88.9)	16 (100)
Type of mutation
H3F3A, n (%)	3 (37.5)	11 (68.5)
HIST1H3B, n (%)	5 (62.5)	4 (25)
HIST2H3C, n (%)	0 (0)	1 (6.5)
ACVR1 detection	8 (88.9)	16 (100)
ACVR1 mutated, n (%)	4 (50)	4 (25)
Wild-type, n (%)	4 (50)	12 (75)

DIPG, diffuse intrinsic pontine glioma; IHC, immunohistochemistry.